(Country; Symbol)


Type Of Agreement

Product Area

Details (Date)

Acambis plc (UK; ACAM)

World Health Organization


Acambis' vaccine, ChimeriVax- E, against Japanese encephalitis

WHO will provide assistance and funding for pediatric trials of the vaccine in endemic countries (11/25)

Advanced Bio/Chem Inc. (OTC BB:AVBC)

University of Texas M.D. Anderson Cancer Center

License agreement

Deal covering diagnosis and monitoring of breast cancer through proteomic analysis of breast ductal fluids

The company licensed rights to the technology on which the two parties have been collaborating (3/15)

Affymetrix Inc. (AFFX)

Translational Genomics Research Institute


TGen will offer geno- typing services to collaborators and NIH programs using Affymetrix technology

The nonexclusive license is for work covering DNA analysis technology; they also began planning future collaborations (2/11)

Alnylam Pharmaceuticals Inc.*

Cold Spring Harbor Laboratory

License agreement

Alnylam licensed technology related to the induction of gene silencing in mammalian cells through RNAi

The license is nonexclusive and covers therapeutic uses of the patent; terms were not disclosed (1/22)

Alteris Therapeutics Inc.*

Duke University and Johns Hopkins University

License agreement

Alteris licensed additional rights to a vaccine (ALT-110) targeting EGFR variant 3

Both universities took an equity stake in Alteris as part of the deal; previous rights were licensed from Thomas Jefferson University (2/18)

Angiotech Pharmaceuticals Inc. (Canada; ANPI)

University of British Columbia (Canada)

License agreement

Angiotech licensed technologies on drug- loaded medical devices and biomaterials

Included in the deal is a jointly developed stent endograft program designed to treat abdominal aortic aneurysms; terms were not disclosed (3/17)

Aphios Corp.*

National Cancer Institute

Material transfer agreement

Deal to access natural products repository of terrestrial plants and marine organisms

Terms of the deal were not disclosed (3/16)

Ariana Pharmaceuticals* (France)

Centre National de Recherche Scientifique (France)

Collaboration extension

Exclusive access to use artificial intelligence technology developed by Ariana and a CNRS lab

The collaboration focuses on further developing the technology to improve the prediction of the quality profile of molecules (12/15)

Aton Pharma Inc.*

National Cancer Institute

Clinical trials agreement

Development of Aton's SAHA in single-agent and combination trials

The deal with the NCI's Cancer Therapy Evaluation Program will support development of the drug (11/20)

Avigen Inc. (AVGN)

University of Colorado

License deal

Treating chronic pain through use of anti- inflammatory cytokines, including IL-10

Avigen gained exclusive rights to patent applications covering the technology; it also expanded its sponsored research agreement with CU-Boulder on research in chronic pain (12/8)

Benitec Ltd. (Australia; ASX:BLT)

Commonwealth Scientific and Industrial Research Organisation (Australia)

License resolution

DNA-directed RNA interference

Agreement resolves dispute on technology among Benitec, CSIRO and the Queensland Department of Primary Industries, allowing all to pursue their fields of interest (12/8)

BioMosaics Inc.*

Sunnybrook and Women's College Health Sciences Centre (Canada)

License deal

A diagnostic test for primary liver cancer that uses a monoclonal antibody to glypican 3

BioMosaics licensed worldwide exclusive rights to the test for detecting liver cancer (11/25)

Binomics Ltd. (Australia; ASX:BNO)

Walter and Eliza Hall Institute (Australia)


Parties signed letter of intent to collaborate on work in ion channels

The focus of the deal will be to identify new lead molecules for treating central nervous system disorders (2/24)

Bruker Daltonics Inc. (unit of Bruker BioSciences Corp.; BRKR)

Leiden University Medical Center (the Netherlands)

Research collaboration

The center acquired mass spectrometry systems from Bruker

The center will provide feedback for clinical research applications; terms were not disclosed (12/4)

Celmed BioSciences Inc. (subsidiary of Theratechnologies Inc.; Canada; TSE:TH)

National Heart, Blood and Lung Institute

Collaboration agreement

Preclinical research using Celmed's photo-dynamic Theralux device

They will test the device for use in graft-vs.-host disease; the plan is to move into a Phase I/II trial after developing and optimizing the methodology (12/10)

Cerus Corp. (CERS)

Johns Hopkins University

License agreement

Cerus acquired certain exclusive rights to the cancer antigen mesothelin

Johns Hopkins gets an up- front payment and would get royalties on sales and revenues from sub-licensing deals; the antigen has applicability in pancreatic and ovarian cancers (1/28)

Cetek Corp.*

M.D. Anderson Cancer Center


To discover and develop drugs targeting cancer and inflammatory diseases

Cetek will use its natural product technologies to isolate drug-like compounds; details were not disclosed (1/7)

ChondroGene Ltd. (Canada; TSE:YDG)

Canadian Arthritis Network

Research collaboration

ChondroGene will make its technology available to network researchers and gain access to their research activity

Projects will be identified, with the goal to advance Chondro-Gene's research and develop diagnostics for osteoarthritis, and then therapeutics (12/2)

Chronogen Inc.* (Canada)

McGill University (Canada)

License agreement

Screening assays for targets and drugs useful in treating lipid disorders linked to atherosclerosis

Chronogen licensed worldwide rights to the technology; the parties also concluded a research collaboration to develop pre-clinical models, to which Chronogen has exclusive rights (12/10)

CombiMatrix Group (CMBX; unit of Acacia as Research Corp.)

St. Jude Children's Research Hospital


To study the genetic variation in the H9 variant of influenza A (bird flu)

The collaboration will investigate the use of chip- based, whole-genome screening of virus strains a tool to monitor the emergence of new strains (3/17)

CombiMatrix Group (CMBX; unit of Acacia Research Corp.)

Case Western Reserve University


To develop a diagnostic for Alzheimer's disease

The work will use the CombiMatrix CustomArray platform; terms of the collaboration were not disclosed (2/23)

CombiMatrix Group (CMBX; unit of Acacia Research Corp.)

Washington University


To develop a system for the synthesis of libraries of diverse, non-nucleic acid molecules

The libraries will be synthesized using CombiMatrix technology; the university is doing the work under a grant from the National Science Foundation (1/20)

Competitive Technologies Inc. (AMEX:CTT)

University of South Carolina Research Foundation

Exclusive agreement

CTI licensed a small- molecule angiogenesis inhibitor with applications in cancer

Terms of the deal were not disclosed (2/24)

CytoGenix Inc. (OTC BB:CYGX)

Baylor College of Medicine


Deal for preclinical testing of a product for lung cancer

The work will combine the company's ssDNA expression vectors and Baylor's aerosol gene delivery technology against a metastasis gene; terms were not disclosed (1/21)

CytoGenix Inc. (OTC BB:CYGX)

Louisiana State University

Research agreement

Deal for preclinical work on a gene shown to cause malignant transformation of tumor cells

The work will use the company's ssDNA expression vector technology to silence the gene; terms of the deal with the university's Health Sciences Center were not disclosed (3/15)

CytoGenix Inc. (OTC BB:CYGX)

University of exas Health Science Center

Agreement for studies

The company's ssDNA technology against a gene to inhibit bacterial reproduction

The university's Houston Medical School will conduct preclinical tests on sepsis in mice (12/15)

CytRx Corp. (CYTR)

University of Massachusetts Medical School


CytRx will fund work at UMMS on gene- silencing technologies for treating cyto-megalovirus diseases

The deal is an expansion of their collaboration; CytRx gets worldwide commcerial rights to resulting discoveries (1/13)

Dharmacon Inc.*

University of Massachusetts Medical School


To use RNA interference to study obesity and diabetes

Dharmacon will design and supply siRNA reagents for UMMS studies on gene targets; terms of the three- ear effort were not disclosed (1/8)

EntreMed Inc. (ENMD)

Children's Medical Center Corp.

License deal

EntreMed transferred to CMCC the rights to the endostatin and angiostatin programs outside of Asia

Alchemgen Therapeutics Inc. got rights in Asia; EntreMed gets upfront payments and would get 20% of any proceeds CMCC derives from the products (1/4)

Genaera Corp. (GENR)

Ludwig Institute for Cancer Research (Germany)


Two-year extension on deal to discover and develop genes and proteins

The focus is on finding pharmaceutical targets and therapeutics, and includes work on interleukin-9; terms were not disclosed (3/8)

Genaissance Pharmaceuticals Inc. (GNSC)

Tokyo Women's Medical Center (Japan)

Purchase agreement

HAP typing services for use in a study on drug response

Genassiance will provide the services; terms were not disclosed (12/4)

Genedata AG* (Switzerland)

University of Minnesota


Extension of license to Genedata's Expressionist, a computational system for large-scale gene expression analysis

The university's Supercomputing Institute for Digital Simulation and Advanced Computation is using the technology in multiple areas (12/2)

GeneMax Corp. (Canada; OTC BB: GMXX)

The University of British Columbia (Canada)

License agreement

GeneMax got an exclusive worldwide license to an assay technology used for drugs that regulate immune responses

GeneMax subsidiary GeneMax Pharmaceuticals Inc. got the license; terms were not disclosed (2/19)

Genencor International Inc. (GCOR)

U.S. Army Edgewood Chemical Biological Center

License agreement

For enzymes to decon- taminate certain organo-phosphateased nerve agents, such as sarin

Genencor's license includes exclusive rights to commercialize the technology for all applications (2/19)

Generex Biotechnology Corp. (GNBT)

Chinese Academy of Science


To develop a SARS vaccine

The effort will combine work at the academy with Generex's Antigen Express technology for enhancing vaccine potency; terms were not disclosed (2/23)

GenMab A/S (Denmark; CSE:GEN)

Sanquin Blood Supply Foundation (the Netherlands)

Research collaboration

To develop an improved treatment for hemophilia patients who don't respond to Factor VIII

GenMab will support a research program at Sanquin to validate the approach, and has an option to license the technology (12/16)

GenOhm Sciences Inc.*

University of Rochester

License agreement

GenOhm licensed nucleic acid synthesis and amplification technology

The coexclusive license will be used to develop diagnostic assays for identification of gene sequences (2/13)

GenoMed Inc.*

National Institute of Allergy and Infectious Diseases


To test the company's compounds in tissue culture assays

The NIAID will test compounds to evaluate activity against influenza, West Nile virus and SARS (12/18)

GMP Companies Inc.*

University of Michigan

License and sponsored research agreement

Class of compounds designed to treat auto- immune diseases and some forms of cancer

GMP licensed the cytotoxic benzodiazepine compounds and will provide UM research funding, license fees, preclinical milestones and sales royalties (12/11)

Health Discovery Corp. (OTC BB:HDVY)

University of Texas M.D. Anderson Cancer Center

Discovery agreement

Biomarkers and path- ways in prostate cancer

The company was granted first option to a worldwide, royalty-bearing license to products discovered using the company's technology (1/26)

HemispherX Biopharma Inc. (AMEX:HEB)

New York Hospital

Clinical program

To conduct a clinical program for West Nile virus

The program will include testing Alferon N injection for the virus; the hospital will seek government support for testing (1/20)

HemispherX Biopharma Inc. (AMEX:HEB)

Vanderbilt University

Clinical program

To conduct a clinical program on SARS

The program includes testing Alferon N injection for the virus; the university will seek government support for testing (1/13)

Hudson Health Sciences Inc.*

Yale University and the State University of New York

License agreement

Hudson licensed IPdR, a radiosensitizer being developed for brain cancer

Details of the deal were not disclosed; Hudson expects to begin Phase I trials in 2004 (3/1)

Immtech International Inc. (AMEX:IMM)

University of North Carolina and Medicines for Malaria Venture (Switzerland)

Development partnership

Agreement to launch trials of malaria drug DB289 in Africa, Asia and South America

Immtech will carry out clinical development work, UNC will provide research support and MMV will provide oversight and funding (12/3)

Insmed Inc. (INSM)

University of Rochester School of Medicine


To test Insmed's SomatoKine for treating myotonic dystrophy, a type of adult muscular dystrophy

The university will get up to $5M from the National Institutes of Health and up to $1.5M from the Muscular Dystrophy Association to research therapies (1/7)

Ingenium Pharmaceuticals AG* (Germany)

Max Plank Institute (Germany)


Ingenium will provide genetic mouse models to the institute

The models were developed with Ingenium's Ingenotyping platform; details were not disclosed (12/19)

Ingenium Pharmaceuticals AG* (Germany)

German National Research Center for Environment and Health GmbH


For Ingenium to access an additional murine tissue archive

The deal is the second licensing agreement between the parties; details were not disclosed (12/19)

Inovio A/S* (Norway)

Navy Medical Research Center

Cooperative Research and Development Agreement

To evaluate Inovio's electroporation technology for delivery of Navy DNA vaccines

The work will start with experiments in large animal models; details were not disclosed (12/30)

Integrated BioPharma Inc. (AMEX:INB)

Fraunhofer USA Inc.'s Center for Molecular Biotechnology

License agreement

Integrated acquired exclusive rights to technology for producing and testing human therapeutic proteins in plants

Integrated will pay up-front and potential royalties on resulting products in exchange for broad rights to the intellectual property (1/13)

Integrated BioPharma Inc. (AMEX:INB)

The Institute for Cancer Prevention Inc.


To jointly research, develop and test compounds for anti- carcinogenic activity

Integrated has exclusive rights to resulting discoveries and would pay the institute royalties on sales; the initial focus is on selenium compounds (1/6)

Kemin Pharma (subsidiary of Kemin Industries Inc.; Belgium)

U.S. Army Medical Research Institute for Infectious Diseases


To screen Kemin's library of carbohydrate- based small molecules against SARS and smallpox

Terms of the deal were not disclosed (12/8)

Keryx Biopharmaceuticals Inc. (KERX)

Four universities

Access agreement

KRX-101 (sulodexide) in the treatment of various diseases

Researchers from Vanderbilt University, the University of British Columbia, Baylor College of Medicine and Thomas Jefferson University will study the drug under Keryx's open-access program (3/9)

Keryx Biopharmaceuticals Inc. (KERX)

University of Michigan

Access agreement

KRX-101 (sulodexide) in the treatment of cardiovascular injury

University researchers will assess the oral heparinoid compound's therapeutic potential in myocardial damage (11/25)

LION Bioscience AG (Germany; LEON)

European Bioinformatics Institute

Expansion of relationship

LION is letting the EBI and other academic institutions use its SRS software technology

The institutions can use the SRS without restrictions; the deal also includes joint research efforts in bioinformatics (3/17)

LION Bioscience AG (Germany; LEON) and DigiGenomics Co. Ltd.*

Wan Fang Municipal Hospital of Taipei (Taiwan)

Development agreement

Deal to develop a SARS Knowledge Management System in Taiwan

They will use LION's SRS relational module in the effort; terms were not disclosed (3/10)

Metabolon Inc.*

Massachusetts General Hospital and the University of Pittsburgh School of Medicine


Parties will study biomarkers and therapeutic targets for amyotrophic lateral sclerosis

The work is being funded by the ALS Association; funding is for one year and could be renewed following release of initial data (2/12)

Microscience Ltd.* (UK)

U.S. Naval Medical Research Center

Cooperative Research and Development Agreement

Preclinical evaluation of a Microscience oral vaccine for anthrax

Microscience will provide its spi-VEC delivery system for evaluation against NMRC models of efficacy; terms were not disclosed (12/8)

Molecula Research Laboratories LLC (subsidiary of CalbaTech. Inc.; OTC BB: CLBE)

Carnegie Institution

Nonexclusive license

Molecula got rights to U.S. Patent No. 6,506,599 on genetic inhibition by double-stranded RNA

Molecula said the rights allow it to compete in the RNAi market; terms were not disclosed (12/15)

Morphotek Inc.*

National Cancer Institute

Cooperative Research and Development Agreement

To develop therapeutic antibodies to a cancer- associated protein identified at the NCI

Morphotek will apply its Morphodoma antibody technology and the NCI will evaluate the antibodies in various solid tumors; terms were not disclosed (1/12)

MWG Biotech AG* (Germany)

Alimentary Pharmabiotic Centre (Ireland)

Supply and services agreement

MWG will support the creation of a micro- array facility at APC

APC at the University of Cork will order a range of products and services; terms were not disclosed (12/4)

Nastech Pharmaceutical Co. Inc. (NSTK)

Carnegie Institute

License agreement

Nastech got a nonexclusive license to the Fire and related patents

Nastech plans to use the siRNA technology in drug research and development; terms were not disclosed (2/2)

Neurochem Inc. (Canada; NRMX)

Institute for Biological Sciences (Canada)


Neurochem is working with the institute's National Research Council on conjugated vaccines

The focus is on Alzheimer's disease; Neurochem would own resulting products; terms were not disclosed (1/20)

NitroMed Inc. (NTMD)

Universities of Edinburgh and St. Andrews (UK)

License agreement

For R&D of NitroMed's nitric oxide-donor drugs for treating acute renal failure

NitroMed has a right of first refusal to commercialize resulting discoveries; the deal was made in conjunction with the Wellcome Trust (2/9)

NitroMed Inc. (NTMD)

Boston University Schoolof Medicine

Research collaboration

To support basic research into clinical and pharmacologic roles of nitric oxide

To support the program, NitroMed is opening a research facility in BU's BioSquare; terms were not disclosed (12/15)

Norak Biosciences Inc.*

National Cancer Institute

Research evaluation agreement

Deal to allow the NCI to evaluate Norak's Transfluor technology to screen GPCR cancer targets

Terms of the deal were not disclosed (1/6)

Onyvax Ltd. (UK)

The Mayo Clinic

License agreement

Onyvax got rights to develop a vaccine for ovarian cancer

Terms of the exclusive, world- wide license were not disclosed (1/15)

Oxford BioMedica plc (UK; LSE:OXB)

The Foundation Fighting Blindness

Development support

Preclinical studies of the company's vision-loss product RetinoStat

The foundation will fund proof- of-principle studies using the LentiVector gene delivery system (11/27)

Panacea Pharmaceuticals Inc.*

Walter Reed Army Institute of Research

Collaborative Research and Development Agreement

They will evaluate PAN-811 and its deriv- atives as neuropro- tectants for global and focal ischemia

Panacea will work with the institute's Division of Neurosciences, Department of Neuropharmacology and Molecular Biology; terms were not disclosed (3/17)

Pharmetix Corp.*

University of Glasgow (UK)

Company formation

Parties collaborated to form a new company, Grannus BioSciences Ltd.

They will develop an anti-inflammatory, thymosin beta 4 sulphoxide, which was discovered at the university (2/12)

Plantacor Inc.*

Texas A&M University

License agreement

License to technology related to substituted diindolymethane ana- logues from cruciferous vegetables

Plantacor got an exclusive license to develop resulting products for treating cancers and other diseases; terms were not disclosed (1/21)

Praecis Pharmaceuticals Inc. (PRCS)

National Cancer Institute

Clinical trials agreement

PPI-2458, a methionine aminopeptidase type-2 inhibitor

They will work to develop a plan for clinical trials in various cancers; the drug is in a Phase I trial in non-Hodgkin's lymphoma (12/10)

Prolexys Pharmaceuticals Inc.*

Whitehead Institute for Biomedical Research

Research collaboration

Use of Prolexys' HySpec platform to investigate interactions between small molecules and proteins

The two-year deal calls for proteomic analysis by Prolexys of compounds at the institute for cancer applications; terms were not disclosed (12/5)

ProSkelia SAS* (France)

German Cancer Research Center

License agreement

ProSkelia licensed technology related to signaling pathways involving Kremen and DKK

The license covers use in bone diseases; the center gets R&D funding as well as potential mile- stones and royalties (3/3)**

Proteome Sciences plc (UK; LSE:PRM) disease and vCJD

UK Medical Research Council


To identify differential protein expression in Creutzfeld-Jacobs

The goal is to develop diagnostics and treatments (11/26)**

Protiveris Inc.*

University of Tennessee- Battelle

License deal

Worldwide rights to sensor technologies

Protiveris acquired rights and will apply the technology to micro- cantilever measurements of bio- molecular interactions (12/3)

ProtoKinetix Inc. (Canada; OTC BB:PKTX)

University of Michigan

Exclusive option agreement

The option is for development of drugs for breast cancer based on mammastatin

Specific terms of the deal were not disclosed (2/2)

Ricerca Biosciences LLC*

Cleveland Clinic


Initial development of a drug therapy that uses cobalamin (vitamin B12) to carry a cancer drug

They plan to take the product to the IND stage, then license it out for further development and marketing (1/26)

Samaritan Pharmaceuticals Inc. (OTB BB:SPHC)

Georgetown University

License agremeent

Parties finalized deal on university's patents related to modulating serum cortisol levels

Samaritan said second- eneration compounds hold promise in a number of disease areas; terms were not disclosed (3/11)

Samaritan Pharmaceuticals Inc. (OTB BB:SPHC)

Georgetown University

Collaboration expansion

Expanding development scope in core areas of AIDS, Alzheimer's, cancer and cardiovascular diseases

Samaritan is increasing its funding and continues to have first right of refusal to exclusively license the results; the deal was extended five years to 2013 (2/9)

Sequenom Inc. (SQNM)

Health Protection Agency (UK)


To apply Sequenom's MassArray technology in the genetic identification and differentiation of microbes

The goal is to develop genetic markers that differentiate pathogenic from nonpathogenic strains of the microbes; terms were not disclosed (1/22)

Sidec Technologies AB* (Sweden)

University of Alabama at Birmingham


To provide a solution for structure-based drug design

Sidec and UAB's Center for Biophysical Sciences and Engineering will co-market services that pair their technologies (12/12)

Sinovac Biotech Ltd. (China; OTC BB: SNVBF)

Center for Disease Control of China


Development of a vaccine for human influenza

The effort is part of the Key Science-Technology Project in China(3/9)

Synthetic Blood International Inc. (OTC BB:SYBD)

Researchers at two universities


Preclinical testing on SBI's Oxycyte product

SBI said the work could lead to development plans in cardiac bypass and valve surgery (12/17)

Targeted Genetics Corp. (TGEN)

International AIDS Vaccine Initiative and Columbus Children's Research Institute


Three-year extension of deal to support TGEN's manufacturing of clinical supply and preclinical studies to evaluate HIV antigens in a multi- component AIDS vaccine

Targeted Genetics is expected to receive $10.7M in funding in 2004; separately, IAVI also will fund clinical trials of tgAAC09, a rAAV-based AIDS vaccine in Phase I trials; the February 2002 deal was extended through 2006 (1/8)

Third Wave Technologies Inc. (TWTI)

Armed Forces Institute of Pathology

Purchase agreement

Third Wave's Invader analyte-specific reagents for genetic screening

The institute will use the system to test military personnel for genetic mutations associated with cystic fibrosis (12/9)

Tm Bioscience Corp. (Canada; OTC BB: TMBIF)

Technology Partnerships Canada

Development agreement

Support of Tm project to develop five genetic tests by 2006

TPC is contributing C$7.3M (US$5.6M) to the effort and would get royalties on resulting products, as well as Tm warrants worth C$2.5M (12/3)

Vertex Pharmaceuticals Inc. (VRTX)

Oregon Health & Science University


To discover and develop therapies aimed at various diseases

Vertex will fund work for three years and fund a stipend for graduate researchers; as part of the deal OHSU dropped litigation against Vertex and got an exclusive license to certain Vertex patents (12/17)

Vical Inc. (VICL)

Centers for Disease Control and Prevention

License agreement

Vical got additional rights to commercialize a West Nile virus vaccine

Vical is developing the vaccine, which uses its delivery technology, with an NIH unit (1/29)

Vion Pharmaceuticals Inc. (VION)

University of Innsbruck (Austria) and Austria Wirtschaftsservice Gesellschaft mbH

Research collaboration and option agreement

Vion will investigate cancer compounds over a 17-month option period

Vion is paying $25,000 up front and would pay $75,000 to exercise an option for worldwide rights; it also would pay milestones and royalties (12/4)

Viragen Inc. (AMEX:VRA)

Roslin Institute (UK)

License agreement

The parties extended Viragen's rights to avian transgenic biomanufacturing technology

The two-year extension continues to provide Viragen worldwide rights to commercialize the technology (3/8)

Zentaris GmbH (subsidiary of AEterna Laboratories Inc.; Canada; AELA)

University of Montpellier (France) and University of Milan (Italy)

Development agreements

Ghrelin antagonist compounds that could have applicability in obesity

Zentaris will support work at the universities in exchange for exclusive worldwide rights (3/11)

Zentaris GmbH (subsidiary of AEterna Laboratories Inc. Canada; AELA)

Universities of Jena and Munster (both in Germany)

Development agreements

Zentaris gets access to technology in the area of proteins of the cytoskeleton, for oncology applications

Researchers at the universities will design, screen and pharmacologically investigate compounds from the class; Zentaris will support research in exchange for exclusive rights (3/11)


This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes date item ran in BioWorld International.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.